NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of… Read More
Delcath Systems, Inc. (OTCMKTS: DCTH) stock rose 8.81% on September 7th, 2018 and continued its bullish momentum Monday, rising over 14.3% on 10th September, 2018...
The post Why Delcath Sys… Read More
Not long ago, I received a call from an investor relations representative who wanted to know if I’d be interested in hearing about a small biotech company with a drug candidate in Phas… Read More
I recently received a call from an investor relations representative who wanted to know if I’d be interested in hearing about a small biotech company with a drug candidate in Phase 2 t… Read More
Trial Continues on Scheduled Path with Expected Completion of Enrollment by June 2019 NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (OTCQB: DCTH), an interventional… Read More
The company’s lead candidate is tivozanib, which is to treat renal cell carcinoma (RCC), a common type of kidney cancer. The initial symptoms of RCC often include blood in the urine… Read More